Coherus Oncology (CHRS) Common Equity (2013 - 2026)
Coherus Oncology (CHRS) posted Common Equity of $78.6 million for Q1 2026, up 28.86% sequentially from $61.0 million in Q4 2025, and up 142.85% YoY from $32.4 million in Q1 2025.
Coherus Oncology (CHRS) Common Equity (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Common Equity for 14 years, with the latest figure at $78.6 million in Q1 2026.
- Quarterly Common Equity rose 142.85% year-over-year to $78.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.6 million (up 142.85% YoY) and the FY2025 annual result came in at $61.0 million, up 146.23% from the prior year.
- Common Equity grew to $78.6 million in Q1 2026 per CHRS's latest filing, from $61.0 million in the prior quarter.
- Over five years, Common Equity peaked at $119.8 million in Q2 2025 and troughed at -$196.5 million in Q1 2023.
- A 5-year average of -$68.5 million and a median of -$88.0 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity slumped 1664.17% in 2023, then jumped 242.47% in 2025.
- Over 5 years, Common Equity stood at -$137.4 million in 2022, then slumped by 40.76% to -$193.4 million in 2023, then surged by 31.76% to -$132.0 million in 2024, then jumped by 146.23% to $61.0 million in 2025, then climbed by 28.86% to $78.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $78.6 million, $61.0 million, and $87.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 9.79 Bn |
| 10 | Coherus Oncology | 215.97 Mn | 110.66 Mn | 10.07 Mn | 60.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.84 Mn |
| Mar 31, 2026 | 78.62 Mn |
| Dec 31, 2025 | 61.01 Mn |
| Sep 30, 2025 | 87.77 Mn |
| Jun 30, 2025 | 119.83 Mn |
| Mar 31, 2025 | -183.47 Mn |
| Dec 31, 2024 | -131.99 Mn |
| Sep 30, 2024 | -87.97 Mn |
| Jun 30, 2024 | -84.11 Mn |
| Mar 31, 2024 | -81.84 Mn |
| Dec 31, 2023 | -193.43 Mn |
| Sep 30, 2023 | -133.60 Mn |
| Jun 30, 2023 | -174.76 Mn |
| Mar 31, 2023 | -196.51 Mn |
| Dec 31, 2022 | -137.42 Mn |
| Sep 30, 2022 | -97.13 Mn |
| Jun 30, 2022 | -22.63 Mn |
| Mar 31, 2022 | 12.56 Mn |
| Dec 31, 2021 | 97.73 Mn |
| Sep 30, 2021 | 130.76 Mn |